Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry-Reference-Cited by-同舟云学术

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

Published:2009-02-19 Issue:1 Volume:11 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Zell Jason A,Tsang Walter Y,Taylor Thomas H,Mehta Rita S,Anton-Culver Hoda

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr2225.pdf

Reference42 articles.

1. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M: AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 2002, New York: Springer-Verlag, 6

2. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH: Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst. 2005, 97: 966-975.

3. Tai P, Yu E, Shiels R, Pacella J, Jones K, Sadikov E, Mahmood S: Short- and long-term cause-specific survival of patients with inflammatory breast cancer. BMC Cancer. 2005, 5: 1-10. 10.1186/1471-2407-5-1.

4. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN: Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995, 4: 715-734.

5. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobagyi GN: Trends for inflammatory breast cancer: is survival improving?. Oncologist. 2007, 12: 904-912. 10.1634/theoncologist.12-8-904.

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial;Gland Surgery;2024-03

2. Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy;Cancer Research Communications;2024-01-24

3. ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer;Scientific Reports;2024-01-02

4. The loss of progesterone receptor predicts more aggressive biological features and worse outcomes in estrogen receptor-positive and HER2-negative inflammatory breast cancer;2023-08-10

5. Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer;The Breast;2023-06